Navigation Links
Common Heart Drugs May Hamper Blood Thinner
Date:10/27/2008

Calcium channel blockers could inhibit Plavix action, study says

MONDAY, Oct. 27 (HealthDay News) -- Calcium channel blocker drugs, which are widely prescribed for coronary conditions, might reduce the effect of the clot-preventing drug Plavix, a new study says.

Calcium channel blockers appear to inactivate an enzyme essential for the activity of Plavix, said the report by Austrian physicians published online Oct. 28 in the Journal of the American College of Cardiology.

Studying 200 people who were taking Plavix after artery-opening procedures and stent placement, the University of Vienna researchers found a higher level of activity of platelets -- the blood cells that can clump together to form blood clots -- in those also taking calcium channel blockers.

"Moreover, intake of calcium channel blockers was associated with adverse clinical outcome," the researchers wrote.

Is the report something that doctors and people taking Plavix should worry about?

"We don't know," said Dr. Neal S. Kleiman, director of the cardiac catheterization laboratory at the Methodist DeBakey Heart and Vascular Center in Houston. He wrote an accompanying editorial in the journal.

"Is it possible that it is clinically significant? Yes, it is," Kleiman said. "Is it a test-tube finding that doesn't mean much? That is possible, too."

Those questions can be answered by analyzing studies containing information about people taking both drugs, Kleiman said. "There are many studies that have large databases that can be queried," he said. "There are ways to query them and see if there is an increased risk of stent thrombosis in patients taking calcium channel blockers."

Plavix (clopidogrel) is recommended for anyone having a stent implanted, to reduce the incidence of thrombosis, which is blockage of the reopened artery. One problem for the working cardiologist is that people who have stents -- wire mesh tubes -- implanted usually are taking a number of other drugs, often including calcium channel blockers, Kleiman said. Calcium channel blockers are commonly prescribed for high blood pressure and the chest pain called angina, he noted.

"What you do with the information in this report is that you remember it," he said. "When a patient comes to you with a long list of medications, if possible, you try to avoid those that might have interactions."

There is a role in the decision-making for the people taking the drugs, Kleiman said. "The patient should ask, 'Why am I taking these medications, what do they do, do I need to be on all of them?'" he said. "The answer is usually 'yes.' "

Dr. John H. Alexander, an associate professor of medicine at Duke University School of Medicine's Division of Cardiovascular Medicine, said the finding could affect medical practice. "The clinical impact is to lead physicians to look for alternatives to calcium channel blockers," he said. "There are lots of alternatives, including beta blockers and ACE inhibitors."

The report shows the need for continual appraisal of commonly used medical treatments, Alexander added. "Clopidogrel has been used in millions of patients for a long time, and we are still starting to learn about potential interactions," he said. "This is a drug interaction we should have thought of earlier."

More information

Learn more about calcium channel blockers from the Texas Heart Institute.



SOURCES: Neal S. Kleiman, director, cardiac catheterization laboratory, Methodist Debakey Heart and Vascular Center, Houston; John H. Alexander, M.D., associate professor, medicine, Duke University School of Medicine's Division of Cardiovascular Medicine, Durham, N.C.; Oct. 28, 2008, Journal of the American College of Cardiology, online


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. UK junior doctors gaining less experience of common procedures
2. New insights into common knee injuries
3. High and mighty: first common height gene identified by researchers behind obesity gene finding
4. Figure Skater Peggy Fleming, HealthSaver Says: Take Pains For Back Strains, 2nd Most Common Doctor Complaint
5. Exelixis Commences Public Offering of Common Stock
6. Common misdiagnosis: most women believe they have a yeast infection when they dont
7. Business Executives Discuss National Health Care Reform at Conference Sponsored by The Century Foundation, with Support from The Commonwealth Fund, and AARP
8. New Expert Report Dispels Common Myths About Aspartame
9. Common Foot Myths Trip Us Up
10. AHPC Holdings, Inc. Announces Intent to Deregister Common Stock With Securities and Exchange
11. Allergy-Induced Asthma More Common in Affluent Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... 2017 , ... At Hallmark Nameplate, their commitment to quality is what sets ... ISO 13485. This certification is another way they are making constant strides to provide ... they need. , The ISO 13485 Certification is a major accomplishment for Hallmark Nameplate ...
(Date:1/18/2017)... ... January 18, 2017 , ... Michael ... new website for its Center for Biosimilars, announced Michael J. Hennessy Associates, Inc. ... in the field of biosimilars through thought leader interaction in, live video and ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... ... problems ranging from gum disease to enamel erosion, and those dental problems can ... Department of Public Health, many pregnant women are failing to get the dental ...
(Date:1/17/2017)... ... January 17, 2017 , ... Anesthesia Progress – Everyone ... choose the best drug option for each patient. Dentists have several general anesthesia alternatives ... outcomes. , Researchers from the Tokyo Dental College in Tokyo, Japan wanted to find ...
(Date:1/17/2017)... ... January 17, 2017 , ... For breast cancer clinicians and researchers ... those who desire a more intimate review and analysis of its highlights, a novel ... Bedside—is being offered by Imedex on February 4, 2017 in Chicago. Chaired by Kathy ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... 2017   Spotlight Innovation Inc. (OTCQB: ... in the second quarter of 2017, to launch ... to provide relief from chronic pain, is a ... was developed under a licensing agreement with Dr. ... from snake venom. Additionally, Caretta Therapeutics has signed ...
(Date:1/18/2017)... , Jan 18, 2017 Research and Markets ... Vomiting Drugs Market 2017-2021" report to their offering. ... The global CINV drugs ... 2017-2021. Global Thoracic Surgery Market 2017-2021, has been ... experts. The report covers the market landscape and its growth prospects ...
(Date:1/18/2017)... -- In China , we say Health ... of China,s Healthy Strategy originates. 2016 ... Economic and Social Development of the People,s Republic ... state council of the People,s Republic of China ... development plan, identifying medical devices as one of the main ...
Breaking Medicine Technology: